Zacks Investment Research downgraded shares of REVANCE THERAP (RVNC) from N/A to NEUTRAL on December 11, 2014, with a target price of $18.90.
Revance Therapeutics, Inc. is a biopharmaceutical company which focuses on the development, manufacture and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications. The company's technology platform includes TransMTS (R). Its lead product candidate consists of RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. Revance Therapeutics, Inc. is based in Newark, United States.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on REVANCE THERAP (RVNC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment